🏛️ Verified NIH Record • Updated 2026-07-28
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients (NCT02362503)
A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: ViiV Healthcare
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (139 Sites)
Showing the first 25 of 139 sites.
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Palm Springs, California
- GSK Investigational Site — San Francisco, California
- GSK Investigational Site — Denver, Colorado
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Washington D.C., District of Columbia
- GSK Investigational Site — Washington D.C., District of Columbia
- GSK Investigational Site — Ft. Pierce, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — West Palm Beach, Florida
- GSK Investigational Site — Wilton Manors, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Savannah, Georgia
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Indianapolis, Indiana
- GSK Investigational Site — Baltimore, Maryland
- GSK Investigational Site — Baltimore, Maryland
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Southfield, Michigan
- GSK Investigational Site — Hillsborough, New Jersey
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infections
- Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention — Chicago, Illinois
- The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City — New York, New York
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults — Birmingham, Alabama
- Clinical Decision Support for PrEP — Los Angeles, California
- Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care — Baltimore, Maryland
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV — Las Vegas, Nevada
Explore by condition: All HIV Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.